[Chinese expert consensus on integrated lipid management in HIV/AIDS].

Human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) are one of the global public health issues concerning health of human beings. Dyslipidemia is one of the major risk factors for cardiovascular events, while elevation of plasma cholesterol levels is associated with the onset of over 50% coronary heart disease. The incidence risks of cardiovascular diseases are higher in HIV/AIDS patients than those in normal populations. In addition to conventional risk factors, viral duplication and suboptimal treatments increase risks of atherosclerotic coronary vascular disease (ASCVD) in HIV/AIDS patients. Thus, a deep knowledge of lipid metabolism and dysregulation profiles, an efficient control of conventional ASCVD risk factors, as well as strengthened measures to lipid management, are of significance to improve long-term prognosis and life quality for HIV/AIDS patients. However, up to date, there is no particular consensus on lipid management for HIV/ADIS populations under long-term antiretroviral therapies (ART). Hereby, based on current status quo of ART in China and frontier achievements of fundamental researches and clinical trials, we invited domestic experts in fields of infectious diseases and cardiovascular diseases to compose this expert consensus on the integrated management of lipid in HIV/AIDS patients in China.人类免疫缺陷病毒（HIV）感染和获得性免疫缺陷综合征（AIDS）是影响人类健康的全球性公共卫生问题之一。血脂异常是心血管事件发生的主要危险因素，胆固醇水平升高与全球超过50%的冠心病发病相关。HIV/AIDS患者的心血管疾病风险高于一般人群，除了传统风险因素以外，HIV病毒复制和抗病毒治疗不良反应等因素均增加了动脉粥样硬化性心血管疾病（ASCVD）风险。深入认识HIV/AIDS患者群体血脂代谢特征和变化规律，积极控制ASCVD传统风险因素，强化患者血脂异常管理，对降低ASCVD发生风险，改善患者远期预后和生活质量都具有重要意义。目前，我国尚无针对艾滋病的专家共识指导接受长期抗反转录病毒治疗（ART）的HIV/AIDS患者的血脂管理。基于这一现状，我们邀请国内感染病学和心血管疾病领域的专家，结合我国抗病毒治疗实际和前沿基础/临床研究成果，共同编写HIV/AIDS患者血脂综合管理中国专家共识。.